Login to Your Account



Biopharm America

Dress for Success: Panel Mulls Best Early Stage Deal Chances

By Randy Osborne
Staff Writer

Thursday, September 19, 2013
BOSTON – Even with a solid strategic fit, quality assets on the table and the likelihood of reimbursement by payers, intellectual property (IP) glitches can hurt a deal, warned Sanjeev Munshi, director of worldwide licensing and acquisition for Merck & Co. Inc.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription